uniQure (NASDAQ:QURE) Stock Price Up 8.7% – What’s Next?

Shares of uniQure N.V. (NASDAQ:QURE) were up 8.7% during mid-day trading on Tuesday . The company traded as high as $51.38 and last traded at $51.5660. Approximately 1,429,167 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 2,414,303 shares. The stock had previously closed at $47.46.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Royal Bank Of Canada raised their price target on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. HC Wainwright increased their target price on uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. The Goldman Sachs Group boosted their price target on uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, June 18th. Weiss Ratings restated a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Finally, Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a research note on Wednesday, June 17th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average price target of $65.00.

uniQure Stock Up 8.0%

The business has a 50-day moving average of $43.78 and a 200 day moving average of $28.88. The company has a market capitalization of $3.56 billion, a PE ratio of -12.78 and a beta of 0.93. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter in the prior year, the business earned ($0.69) EPS. Equities research analysts predict that uniQure N.V. will post -3.74 earnings per share for the current year.

Insider Transactions at uniQure

In related news, insider Kylie O’keefe sold 15,936 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the sale, the insider owned 108,864 shares in the company, valued at approximately $2,945,859.84. The trade was a 12.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jack Kaye sold 21,167 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total transaction of $982,995.48. Following the sale, the director directly owned 25,996 shares in the company, valued at approximately $1,207,254.24. The trade was a 44.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 388,229 shares of company stock valued at $16,817,099 in the last 90 days. Company insiders own 4.65% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its stake in shares of uniQure by 6,641.2% in the 2nd quarter. California State Teachers Retirement System now owns 2,423,263 shares of the biotechnology company’s stock valued at $111,615,000 after purchasing an additional 2,387,316 shares during the last quarter. State Street Corp increased its position in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC grew its holdings in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after purchasing an additional 1,705,556 shares during the last quarter. Finally, Orbimed Advisors LLC grew its holdings in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.